Uncategorized
New Prospective, Multicenter Study Presented at SMR Demonstrates Castle Biosciences’ DecisionDx®-Melanoma Test Provides Significant Risk Prediction for Patients with Cutaneous Melanoma, Adding Value to Current Stage-Based Treatment Pathway Decisions
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #2024SMRCongress--Castle will present new data on DecisionDx-Melanoma and DecisionDx-UM at the 21st International Congress of the Society for Melanoma Research (SMR).